影响马西替坦和西乐昔帕患者坚持率的做法 利用肺动脉高压临床站点和患者标准(PERSIST):一项美国定性分析。

IF 2.2 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Pulmonary Circulation Pub Date : 2024-10-11 eCollection Date: 2024-10-01 DOI:10.1002/pul2.12441
Oksana A Shlobin, Gary Bruce, Gabriela Gomez-Rendon, Martha Kingman, Mohammad Rahman, Frances Rogers, Sean Studer, Tobore Tobore, Colleen McEvoy
{"title":"影响马西替坦和西乐昔帕患者坚持率的做法 利用肺动脉高压临床站点和患者标准(PERSIST):一项美国定性分析。","authors":"Oksana A Shlobin, Gary Bruce, Gabriela Gomez-Rendon, Martha Kingman, Mohammad Rahman, Frances Rogers, Sean Studer, Tobore Tobore, Colleen McEvoy","doi":"10.1002/pul2.12441","DOIUrl":null,"url":null,"abstract":"<p><p>This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 4","pages":"e12441"},"PeriodicalIF":2.2000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467788/pdf/","citationCount":"0","resultStr":"{\"title\":\"Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis.\",\"authors\":\"Oksana A Shlobin, Gary Bruce, Gabriela Gomez-Rendon, Martha Kingman, Mohammad Rahman, Frances Rogers, Sean Studer, Tobore Tobore, Colleen McEvoy\",\"doi\":\"10.1002/pul2.12441\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.</p>\",\"PeriodicalId\":20927,\"journal\":{\"name\":\"Pulmonary Circulation\",\"volume\":\"14 4\",\"pages\":\"e12441\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467788/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary Circulation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pul2.12441\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Circulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pul2.12441","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

这项真实世界研究从 23 名医疗保健专业人员(HCPs)和 134 名肺动脉高压患者的角度,探讨了 2019 年至 2022 年期间影响坚持使用马西替坦和 selexipag 治疗的因素。患者/医护人员的持续沟通和教育是坚持治疗的关键因素,早期讨论和处理副作用也是如此。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis.

This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pulmonary Circulation
Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine
CiteScore
4.20
自引率
11.50%
发文量
153
审稿时长
15 weeks
期刊介绍: Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信